CervoMed Inc
CRVO
Company Profile
Business description
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Contact
20 Park Plaza
Suite 424
BostonMA02116
USAT: +1 617 744-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.10 | 47.90 | 0.54% |
| CAC 40 | 7,834.10 | 63.09 | -0.80% |
| DAX 40 | 25,254.21 | 23.01 | 0.09% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,497.94 | 35.99 | 0.34% |
| HKSE | 24,228.47 | 188.13 | 0.78% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 70,502.42 | 555.56 | 0.79% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,739.70 | 53.30 | 0.61% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |